5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate
the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5%
potassium hydroxide solution (Solcera, medical device) versus placebo and
investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is
performed in accordance with both the laws in force for clinical trials with medical devices
and those with medicinal products.